Navigation Links
Novel export-inhibitor shows promise for treating CLL
Date:12/12/2011

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The agent, called KPT-SINE, belongs to a new class of drugs called selective inhibitors of nuclear export (SINE). The agent was developed by Karyopharm Therapeutics Inc. It is designed to kill cancer cells by restoring biochemical pathways that normally cause unhealthy cells to self-destruct through a process called programmed cell death, or apoptosis.

The agent targets a protein called CRM1, which, until now, has not been adequately explored in CLL, the researchers say. During disease progression, cancer cells use CRM1 to shunt certain apoptosis-related proteins out of the nucleus, thereby avoiding cell death.

"We believe that KPT-SINE and other nuclear-export inhibitors may represent a unique, entirely new therapeutic strategy for treating cancer by simultaneously restoring multiple normal cell death pathways," says OSUCCC James research scientist Dr. Rosa Lapalombella who is a co-investigator on the study with Dr. John Byrd, director of the division of hematology and co-director of the OSUCCC James CLL Experimental Therapeutics Laboratory at OSUCCC James.

The researchers hypothesize that KPT-SINE will inhibit CRM1 and keep these regulatory proteins in the nucleus where they can initiate programmed cell death.

Lapalombella will discuss the role of CRM1 inhibition in the treatment of CLL on Monday, December 12, at 7:00 a.m. during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

The study, which used CLL cells from patients and a mouse model of CLL, provides essential proof-of-concept data to desig
'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Novel experimental agent is highly active in CLL patients, interim study shows
2. Researchers identify a novel therapeutic approach for liver cancer
3. Novel drug wipes out deadliest malaria parasite through starvation
4. Novel approach to treating breast cancer shows great promise
5. Wayne State receives $1.9 million from NIH to create novel cystic fibrosis treatments
6. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
7. Wayne State University to study novel treatment for antibiotic-resistant bacteria
8. Novel, noninvasive measurement a strong predictor for heart failure in general population
9. UK HealthCare surgeons are first to perform novel procedures prior to transplant
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. Novel strategy stymies SARS et al.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mountain View, CA (PRWEB) July 29, 2014 ... officially released a new product called BNatrl Silver ... said Lis Herrey, CEO and spokesperson for BNatrl LLC. ... and your loved ones from harmful pathogens and microbes.” ... renewable energy, and clean water products, with 10 percent ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm traditionally ... care industry veteran Daryl Demonbreun and former St. Thomas ... company’s ambitious plans to grow into a full-service health ... along at a steady pace for nearly 20 years, ... says Bob Maier, founder and chief executive officer of ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According ... Market by Type (Swipe And Area), Material (Optical ... Government, Defense, Healthcare, Commercial Security and Banking & ... to 2014 - 2020", published by MarketsandMarkets, the ... $14.35 Billion by 2020, growing at a high ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical ... not only provided a comprehensive and thorough knowledge of ... drug registration but also introduced the practical operation how ... to use the Chinese trial venues to keep drug ... by step. , The audiences of this guidebook are ...
(Date:7/29/2014)... There is controversy over how best to treat patients ... one wait until the cancer comes back or provide ... Now, a new study from Thomas Jefferson ... doctors and patients make a more informed decision. , ... says first author Robert Den, M.D., Assistant Professor of ...
Breaking Medicine News(10 mins):Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2
... LANSING, Mich., Dec. 30 Neogen Corporation,(Nasdaq: NEOG ) announces the ... Quarter Results Webcast, When: Tuesday, January 6, 2009 ... How: Live over the Internet -- Simply log on to ... above., Contact: Terry Maynard of Neogen ...
... for Nearly 20% of 45 plus PopulationCHICAGO, Dec. 30 ... be your health. According to a recent AARP ... are suffering health problems due to financial stress. ... many Americans are facing because of the current economic ...
... - Stubbing Out Your 5 a Day Habit ... , Leading Child Trust Fund provider, ... decide,to give up smoking as their New Year,s resolution to ... futures. , According to figures from ...
... New Year,s resolutions often include being more careful, ... behavior, such as drug use. But new research ... seekers by psychologists--face an uphill battle in keeping ... their brains process dopamine. The research reveals that ...
... Committee for Quality,Assurance and the American Diabetes Association ... Barnett, M.D., Mirela Sturzu,M.D., Rudolf Teschan, M.D., and ... Recognition Program for providing quality care to,patients with ... and Zaki practice at the Aurora Health Center, ...
... CORONA, Calif., Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... and specialty branded pharmaceuticals,today announced that its subsidiary, ... United States Food and Drug Administration on its,Abbreviated ... estradiol tablets USP, 0.15 mg / 0.02 mg. ...
Cached Medicine News:Health News:Economic Stress Taking Toll on Peoples' Health 2Health News:Urging New Year Quitters to Invest in Their Family's Futures 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Aurora Physicians Receive National Recognition for Quality Diabetes Care 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2
(Date:7/29/2014)... 2014   Health 2.0 announces Bernard Tyson ... physicians Eric Topol , Patrick Soon-Shiong , and ... 2.0 8th Annual Fall Conference this coming Sept. 21-24 ... Health 2.0 is set to host the very first Wearable ... on Consumer Tech & Wearables: Powering Healthy Lifestyles. ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... , NEW YORK ... (Sony) announced today that it has acquired iCyt Mission Technology, Inc. ... cell and disease research, through its U.S. subsidiary, Sony Corporation of ... technologies to enter the flow cytometry business in the life science ...
... , Feb. 9 STD Med, Inc., a manufacturer ... is pleased to announce the acquisition of a new 32,000 sq. ... addition to the current footprint of 120,000 sq. ft. "We are ... financial times," said Steven Tallarida , President STD Med, "we ...
Cached Medicine Technology:Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 2Sony Enters the Flow Cytometry Business in Life Science Field by Acquiring iCyt 3STD Med Inc. Acquires Facility for Manufacturing and Start-Ups 2
... NEAR-SkinT™ Incise Drapes have aggressive ... permeability for extended adhesion. It's made ... for unsurpassed conformability with allow-glare matte ... identification. , ,Available sterile in ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The HYBrite Hybridization System - the hands-free ... Procedures. Now performing fluorescent in situ hybridization ... ever before. HYBrite is the first rapid, ... FISH procedures. Now you can have a ...
... CELL-DYN 4000 uses the power of ... parameters to the hematology laboratory. Fluorescent ... random-access reticulocyte results. Fluorescent DNA staining ... accurate white blood cell values and ...
Medicine Products: